Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model (Q44833573)

6 December 2017

title

Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model (English)

1 reference

6 December 2017

0 references

7

David B Weiner

1 reference

6 December 2017

Miguel Otero

1

1 reference

6 December 2017

Sandra A Calarota

2

1 reference

6 December 2017

Barbara Felber

3

1 reference

6 December 2017

Dominic Laddy

4

1 reference

6 December 2017

George Pavlakis

5

1 reference

6 December 2017

Jean D Boyer

6

1 reference

6 December 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

6 December 2017

1 reference

6 December 2017

volume

22

1 reference

6 December 2017

issue

13-14

1 reference

6 December 2017

page(s)

1782-1790

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

6 December 2017

1 reference

DNA vaccines for viral diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

Revealing the potential of DNA-based vaccination: lessons learned from the hepatitis B virus surface antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

Safety and immunogenicity of intramuscular and intravaginal delivery of HIV‐1 DNA constructs to infant chimpanzees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

Safety and immunogenicity of HIV-1 DNA constructs in chimpanzees.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

T-cell responses induced in normal volunteers immunized with a DNA-based vaccine containing HIV-1 env and rev

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

The immunology of HIV-infected long-term non-progressors--a current view

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

Correlates of protection in HIV infection and the progression of HIV infection to AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

Ongoing trials of immune-based therapies for HIV infection in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

Rate, causes, and clinical implications of presenting with low CD4+ cell counts in the era of highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

Viral reservoirs an impediment to HAART: new strategies to eliminate HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

Characterization of a new class of DNA delivery complexes formed by the local anesthetic bupivacaine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

Immunoadjuvants and analogs of immunomodulatory bacterial structures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

Next generation DNA vaccines for HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

Recent developments in adjuvants for vaccines against infectious diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

Advances in vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

The rational design of vaccine adjuvants for mucosal and neonatal immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

Genetic adjuvants for DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

Cytokines and costimulatory molecules as genetic adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

Interleukin-1 and interleukin-1 fragments as vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

Nucleic acid for the treatment of cancer: genetic vaccines and DNA adjuvants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2 lymphocytes into IFN-gamma-producing cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

Immunomodulation as a treatment strategy for genital herpes: review of the evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

Enhancement of DNA vaccine potency against herpes simplex virus 1 by co-administration of an interleukin-18 expression plasmid as a genetic adjuvant.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

HBV DNA vaccine with adjuvant cytokines induced specific immune responses against HBV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

Co-immunization of rhesus macaques with plasmid vectors expressing IFN-gamma, GM-CSF, and SIV antigens enhances anti-viral humoral immunity but does not affect viremia after challenge with highly pathogenic virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

Co-expression of granulocyte-macrophage colony-stimulating factor with antigen enhances humoral and tumor immunity after DNA vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

Adjuvant effects of IL-1beta, IL-2, IL-8, IL-15, IFN-alpha, IFN-gamma TGF-beta4 and lymphotactin on DNA vaccination against Eimeria acervulina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

Combined administration of plasmids encoding IL-4 and IL-10 prevents the development of autoimmune diabetes in nonobese diabetic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

Immunopotentiation of DNA vaccine against herpes simplex virus via co-delivery of plasmid DNA expressing CCR7 ligands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

Genetic immunization: a new era in vaccines and immune therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.037

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2004.01.037

1 reference

6 December 2017

1 reference